Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis
- PMID: 15248210
- DOI: 10.1002/art.20375
Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis
Abstract
Objective: To investigate whether interactions of sulfasalazine (SSZ) with reduced folate carrier (RFC), the dominant cell membrane transporter for natural folates and methotrexate (MTX), may limit the efficacy of combination therapy with MTX and SSZ in patients with rheumatoid arthritis.
Methods: Human RFC-(over)expressing CEM cells of T cell origin were used to analyze the effect of SSZ on the RFC-mediated cellular uptake of radiolabeled MTX and the natural folate leucovorin. Moreover, both cells with and those without acquired resistance to SSZ were used to assess the antiproliferative effects of MTX in combination with SSZ.
Results: Transport kinetic analyses revealed that SSZ was a potent noncompetitive inhibitor of RFC-mediated cellular uptake of MTX and leucovorin, with mean +/- SD K(i) (50% inhibitory concentration) values of 36 +/- 6 microM and 74 +/- 7 microM, respectively. Consistent with the inhibitory interaction of SSZ with RFC, a marked loss of MTX efficacy was observed when MTX was coadministered with SSZ: up to 3.5-fold for CEM cells in the presence of 0.25 mM of SSZ, and >400-fold for SSZ-resistant cells in the presence of 2.5 mM of SSZ. Importantly, along with diminished efficacy of MTX, evidence for cellular folate depletion was obtained by the demonstration of an SSZ dose-dependent decrease in leucovorin accumulation.
Conclusion: At clinically relevant plasma concentrations, interactions of SSZ with RFC provide a biochemical rationale for 2 important clinical observations: 1) the onset of (sub)clinical folate deficiency during SSZ treatment, and 2) the lack of additivity/synergism of the combination of SSZ and MTX when these disease-modifying antirheumatic drugs are administered simultaneously. Thus, when considering use of these drugs in combination therapies, the present results provide a rationale both for the use of folate supplementation and for spacing administration of these drugs over time.
Similar articles
-
Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.J Rheumatol. 2008 Apr;35(4):562-71. Epub 2008 Mar 1. J Rheumatol. 2008. PMID: 18322994
-
Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs.Rheumatology (Oxford). 2009 Jul;48(7):828-33. doi: 10.1093/rheumatology/kep090. Epub 2009 May 20. Rheumatology (Oxford). 2009. PMID: 19458163
-
[Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].Ter Arkh. 2008;80(5):25-30. Ter Arkh. 2008. PMID: 18590110 Clinical Trial. Russian.
-
Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.Rheumatology (Oxford). 2004 Mar;43(3):267-71. doi: 10.1093/rheumatology/keh088. Epub 2004 Jan 6. Rheumatology (Oxford). 2004. PMID: 14963199 Review.
-
Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions.Br J Rheumatol. 1995 Nov;34 Suppl 2:104-8. Br J Rheumatol. 1995. PMID: 8535640 Review.
Cited by
-
Association of altered folylpolyglutamate synthetase pre-mRNA splicing with methotrexate unresponsiveness in early rheumatoid arthritis.Rheumatology (Oxford). 2021 Mar 2;60(3):1273-1281. doi: 10.1093/rheumatology/keaa428. Rheumatology (Oxford). 2021. PMID: 32940699 Free PMC article.
-
Intestinal absorption of water-soluble vitamins in health and disease.Biochem J. 2011 Aug 1;437(3):357-72. doi: 10.1042/BJ20110326. Biochem J. 2011. PMID: 21749321 Free PMC article. Review.
-
Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.Ann Rheum Dis. 2007 Oct;66(10):1356-62. doi: 10.1136/ard.2006.066662. Epub 2007 Feb 9. Ann Rheum Dis. 2007. PMID: 17293364 Free PMC article. Clinical Trial.
-
Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.Ann Rheum Dis. 2007 Aug;66(8):1059-65. doi: 10.1136/ard.2006.061820. Epub 2007 Feb 16. Ann Rheum Dis. 2007. PMID: 17307765 Free PMC article.
-
Oncology Therapeutics Targeting the Metabolism of Amino Acids.Cells. 2020 Aug 15;9(8):1904. doi: 10.3390/cells9081904. Cells. 2020. PMID: 32824193 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources